New TAVR program and Aortic valve stenosis

Aortic valve stenosis (AS) is the most common valvular heart disease in the elderly. Development of symptoms can include congestive heart failure, angina (chest pain) or syncope (dizziness or fainting) in the presence of severe aortic stenosis warrants surgical intervention to prolong life and improve symptoms. Traditionally, surgical intervention through open heart surgery has been the standard of care. However, elderly population, frequently have other diseases or conditions that makes surgical intervention very high risk. These challenges in the elderly population lead to the development of Transcatheter Aortic Valve Replacement (TAVR). In two randomized trials in the United States (PARTNER and CORE VALVE Trial), TAVR was compared to traditional surgical approach in high risk patients with severe AS. The studies showed that TAVR has similar and even better outcomes to those patients with a traditional surgical approach. Currently, the FDA approved TAVR for high risk patients with symptomatic severe aortic valve stenosis. Given the remarkable outcome with TAVR, Citrus Valley Health Partners is committed for developing an outstanding valvular program to bring this new technology to our community. We are currently building our heart team and partnering with our cardiologists in the community to guarantee the success of our TAVR program.

Dr. Fahed Bitar is the Medical Director at CVHP for interventional cardiology. He has studied in Germany with top TAVR practitioners to become certified in doing the procedure. For more information about the Citrus Valley Heart Center please call (626) 261-4038.

Related Articles

Article Sections

Contact Us

Reason for contacting us?